Stem cells are clonogenic cells that have two remarkable features, the ability to differenti ate into multiple mature cell types (multi potency) and the ability to simultaneously replenish the stem cell pool (selfrenewal), that allow them to sustain tissue develop ment and maintenance 1
. The surge of stem cell research arose when it became clear that all blood cell components are derived from a rare subset of bone marrow (BM) residing haematopoietic stem cells (HSCs), which can be isolated and assayed in vitro and in vivo. Currently, HSCs are the para digmatic and bestcharacterized example of tissuespecific stem cells.
Soon after the discovery of HSCs, studies by Friedenstein and colleagues 2 reported that the BM stroma can generate bone, fat cells, cartilage and reticular cells following hetero topic transplantation (that is, transplantation into a different tissue from that of origin) in mice. This suggested the existence of non haematopoietic BM multipotent precursor cells with skeletal and adipose potential 2, 3 . It was later shown that these precursors were a subset of fibroblastlike cells (defined as colonyforming unit fibroblasts (CFUFs) 4 , in analogy to their haematopoietic counterpart) that could be selected by adherence to plastic surfaces and expanded in vitro. Further stud ies substantiated the ability of cultured cells derived from single CFUFs to proliferate while preserving the ability to differentiate to osteoblasts, adipocytes and chondrocytes in vitro 5 . Multilineage capacity and prolifera tion in vitro were interpreted at the time as indicative of in vivo multi potency and self renewal, the hallmarks of 'stemness' . Thus, the term mesen chymal stem cell (MSC) was coined and gained acceptance to refer to these newly identified precursor cells 6, 7 . Since their original description, stromal cells cat egorized as MSCs based on trilineage (osteo blast, adipo cyte and chondrocyte) potential in vitro have been isolated from the adherent fraction of many adult and embryonic tissues in multiple species [8] [9] [10] [11] (FIG. 1) .
Multipotentiality in vitro, as well as ease of isolation and expansion, rapidly positioned MSCs as promising therapeutic agents in regenerative medicine and made them the subject of intensive clinical research 12 
. Nevertheless, many important aspects regarding MSC biology are still unclear. In this Opinion article, we discuss the wellestablished properties of MSCs cultured in vitro, and focus on how these properties relate to recent studies that are beginning to uncover MSC localization and function in vivo.
Studying MSCs in vitro
Defining MSCs. Stem cells are classically defined by their multipotency and self renewal
. Based on these criteria, the central and most disputed issue is the use of the term MSC. This term was first used to refer to a hypothetical postnatal, multi potent and selfrenewing precursor derived from an original embryonic MSC, the func tion of which was to maintain the turnover of skeletal tissues in homeostasis or tissue repair during adulthood. As described for HSCs, MSCs would lie at the top of the mesenchymal cell hierarchy and progress through discrete stages of differentiation in an orderly manner to give rise to func tionally and pheno typically mature tissues, including bone, smooth muscle, tendons and cartilage 6 . This theoretical model provided an attractive conceptual framework in which the stromal multipotent precursor cell described by Friedenstein was rapidly regarded as the prototypical MSC, despite the fact that such a cell had not been shown to strictly fulfil the attributes conveyed in the term MSC. First, the biological proper ties of multipotent progenitors had mostly been inferred from the analysis of clonal and nonclonal in vitroexpanded popu lations owing to the inability to isolate and assay them directly from tissues. Until recently, the multipotency and selfrenewal of un cultured progenitors had not been fully probed using stringent in vitro and in vivo assays. Furthermore, the existence of a com mon postnatal 'mesenchymal' progenitor has been questioned, as bone and muscle derive from different progenitors during embryonic development, and because whether MSCs give rise to muscle cells in vivo has not been convincingly demonstrated to date. For this reason, alter native names such as osteogenic or skeletal stem cells have been suggested. Regardless of its inaccuracy 13, 14 , the term MSC has remained prevalent to date to designate stromal precursors with triline age potential isolated from the BM and, by extension, from any other mammalian tis sue. Of note, the common use of the name MSC to indistinctively refer to both in vivo precursors and their in vitroexpanded 
Self-renewal
Stem cells also possess the capacity of self-renewal; that is, the ability to undergo numerous cell divisions while retaining their stem cell identity. HSCs have been shown to self-renew: HSCs transplanted into irradiated mice can reconstitute the haematopoietic system, including giving rise to a population of HSCs that can be serially re-transplanted 1 . BM-resident MSCs have also been shown to possess this ability, as their transplantation gives rise to 'ossicles' composed of bone, cartilage and reticular stroma, as well as to a population of serially re-transplantable MSCs 1 . 17, 18 and have been documented to contribute to bone regeneration in animal models of genetic bone disorders 19 . Many studies have further reported mesenchymal stromal cell differentiation into multiple other cell types of mesodermal and non mesodermal origin, including endothelial cells 20 , cardiomyocytes 21 , hepato cytes 22 and neural cells 23, 24 . Nevertheless, such multi potential capabilities of mesenchymal stro mal cells are not universally accepted. There are concerns because of the lack of globally standardized methods for their isolation, expansion and identification, as well as the range of assays used to define terminally differentiated, functionally mature popu lations. Claims for in vivo differentiation into other cell types are equally controver sial, as BMderived mesenchymal stromal cell cultures have been shown to contribute to many tissues following transplantation through fusion with endogenous cells and not through differentiation into mature cell types 25 . How multipotent mesenchymal stromal cells really are remains unclear.
Discrepancies in the reported properties of MSCs might be partially explained by their presence in tissues of diverse precursor types, heterogeneous in nature and origin, that seem similar on the basis of their in vitro characteristics. However, hetero geneity is obvious at the level of mesenchymal stromal cell cultures (reviewed in ReF. 26) , with the presence of clones of different morphologies 8, 27, 28 , proliferative capacities 29 , in vitro multidifferentiation capacities and in vivo abilities to generate bone in ectopic implants 27, 30, 31 . Singlecellderived clones of mesenchymal stromal cells from human umbilical cord progenitors that display varying degrees of multipotency and exten sive selfrenewal in vitro have been shown to generate daughter clones that gradually lose their multilineage differentiation capacity 32 . Together, these observations suggest that conventional mesenchymal stromal cell cultures arise from, and contain, a hetero geneous pool of mesenchymal progenitors or stem cells that can be organized in a hier archical manner, analogous to that of other welldescribed stem cell systems. Beyond MSCs, more primitive multipotent cell sub sets with the potential to give rise to cells of all three germ layers have been proposed to be present within the tissueresident pool of cells and copurify with mesenchymal stromal progenitors. Nevertheless, it should be emphasized that the existence of stem cell populations of such nature, which include MAPCS (multipotent adult progenitor cells) 33 and MUSe cells (multilineage differ entiating stressenduring cells) 34 , is highly controversial, as a detailed characterization of their biological properties and in vivo identities is lacking, to date.
An additional important consideration at this point is that mesenchymal stromal cells derived from various postnatal or embryonic tissues using identical culture conditions display significant differences in colony morphology, differentiation potential and gene expression 8, [35] [36] [37] . This raises the question of whether MSCs from different anatomical locations, selected by classic adherence and in vitro culture methods, are biologically equivalent. Collectively, these results suggest that mesenchymal stromal cell cultures may originate from an array of tissuespecific multipotent precursor cells that are present in native tissues and have diverse degrees of plasticity and selfrenewal. The plastic-adherent cellular fraction of many organs contains stromal progenitor cells that can give rise to colonies of fibroblastic morphology. This cellular subset, known as colony-forming unit fibroblasts (CFU-Fs), totally or partially corresponds to a proposed multipotent progenitor cell population, most probably heterogeneous in nature and origin, that resides in the proximity of blood vessels in all tissues studied so far and has been shown to express pericyte-specific markers (CD146, NG2 (also known as CSPG4) and platelet-derived growth factor receptorβ (PDGFRβ)). When cultured under the appropriate cell densities, colonies derived from single CFU-Fs can be isolated and expanded after multiple passages in vitro (indicated by the curved arrow) without losing their multipotent mesenchymal capacity. These cultured cells, classically referred to as mesenchymal stem cells (MSCs), are now termed multipotent mesenchymal stromal cells. The hallmark that defines mesenchymal stromal cells is their ability to differentiate into osteoblasts, adipocytes and chondrocytes when placed under inductive stimuli. Differentiation into multiple non-mesenchymal mature cell types (such as muscle cells, endothelial cells and neural cells) has been reported but remains a matter of debate.
Studying MSCs in vivo
After years of investigating MSCs out of their native context, little has been learned regarding the identity and function of their precursors in vivo. It is important to note that the fundamental biological properties of mesenchymal stromal cells are likely to be altered by culture conditions and thus should not be directly ascribed to their pre sumed in vivo counterpart, as has often been the case in the published literature. Progress in our understanding of bona fide MSCs largely relies on having the capacity to rec ognize progenitor cells in situ, prospectively isolate them and finally assay their multi potency and selfrenewal capacity in vivo.
Prospective isolation, multipotency and self-renewal. The unequivocal identification of MSCs in vivo has been hindered by their extremely low frequency in tissues 38 and the lack of a distinct MSCspecific immuno phenotype to enable their iso lation. Indeed, cultured human mesenchymal stromal cells express a panel of cell surface markers (such as CD73, CD90 and CD105) and lack endothelial or haematopoietic cell markers (CD31, CD34 and CD45) 16 . Nevertheless, these are not homogeneously expressed throughout stromal cultures and they vary with isolation protocols and passage; therefore, they are not necessarily repre sentative of MSCs in vivo. Several labelling strategies have been used to successfully enrich for CFUFs in human and mouse BM; these include the use of combinations of markers such as STRO1 and CD106 (ReFs 39,40), SSeA4 (also known as FUT4) 41 , CD56, CD271, MSC antigen 1 (MSCA1) and D7FIB (a fibroblast or epithelial cell marker) [42] [43] [44] . Recent studies have provided valuable insight into the identity and physiology of BMresident MSCs by using new markers to track and purify MSCenriched populations and assay them in vivo. Of note, unlike the haematopoietic system, in which haemato poietic reconstitution of myeloablated recipients is the gold standard to assess HSC selfrenewal and differentiation at a single cell level, no universally accepted assay has been established to date to probe for the activity of MSCs in vivo.
Using the capacity to form bone and assemble a functional BM stroma at hetero topic sites as an indication of MSC potential in vivo, one group identified a population of CD146 + perivascular selfrenewing osteoprogenitors that were present in the outermost connective tissue layer covering BM microvessels (known as the adventitia) 45 . Furthermore, in mice combined expression of surface cell antigen 1 (SCA1) and platelet derived growth factor receptorα (PDGFRα) specifies a subset of nonhaematopoietic cells that resides close to arteries and gives rise to osteoblasts, reticular cells and adipo cytes in vivo upon transplantation into an irradiated recipient 46 . Finally, the neural stem cell marker nestin was recently reported to label BMresident MSCs in a selective manner. This study showed for the first time that MSCs are the progenitors of mature osteochondral cell types in the BM under physiological conditions. Nestin + BMderived MSCs could be cultured under nonadherent conditions and could be seri ally transplanted, therefore demonstrating a robust selfrenewal capacity 47 . Together, these studies have convincingly shown the selfrenewing and differentiation potential of a specific population of MSCs in the BM. It remains to be determined whether, and to what extent, the specificity of these markers and the functional charac teristics of these BMresident MSCs can be used to describe MSC populations from different adult tissues.
Perivascular localization in vivo.
A key task for assessing the function of MSCs in vivo is to define their microanatomical localization in situ in diverse organs. efforts to track the identity of tissueresident MSCs have consistently suggested that these cells lie adjacent to blood vessels 48 . evidence for such association came from initial observa tions that pericytes (also known as Rouget cells or mural cells), which are defined by their perivascular location and morphology, display MSClike features 49 . Pericyte derived cultures are similar to mesenchymal stromal cell cultures in terms of morphol ogy and cellsurface antigen expression, and can be induced to differentiate into not only osteo blasts, chondrocytes and adipocytes but also smooth muscle cells and myocytes under appropriate conditions [50] [51] [52] . Cells expressing some mesenchymal stromal cell markers were found to localize to blood vessel walls in human bone marrow and dental pulp 53 . Conversely, MSClike cultures were generated from cells enriched directly from tissues based on expression of pericyte specific markers 54 . However, evidence that pericytes and MSCs are biologically equiva lent has remained indirect for a long time. A recent study identified a combination of markers, such as NG2 (also known as CSPG4), CD146 and PDGFRβ, that seemed to specifically label pericytes in a range of human organs, including fetal and adult skin, pancreas, heart, brain, lung, bone marrow and placenta. longterm cultures derived from prospective pericytes isolated directly from these organs, based on specific expression of those markers, displayed simi lar morphological features to cultured mes enchymal stromal cells, as well as trilineage potential in vitro and osteogenic potential in vivo 55 .
Box 2 | Therapeutic exploitation of mesenchymal stromal cells
Although clinical interest in cultured mesenchymal stem cells (known as mesenchymal stromal cells) initially focused on the potential of their stem cell-like properties for tissue regeneration and repair, the discovery of their paracrine properties markedly increased the range of therapeutic applications for which they are currently studied. Systemic infusion of mesenchymal stromal cells has proved beneficial in different preclinical models of acute lung injury, myocardial infarction, diabetes and multiple sclerosis, as well as renal and hepatic failure 74, 78 . Although the mechanisms underlying the therapeutic effects of mesenchymal stromal cells in these disease models are not well characterized, they are thought to arise partially from the release of a combination of multiple bioactive molecules with anti-inflammatory, antiproliferative, anti-apoptotic and angiogenic properties (reviewed in ReF. 12) . The current hypothesis is that paracrine factors secreted by mesenchymal stromal cells provide protective microenvironmental cues and promote repair by local tissue-resident progenitor populations, thereby explaining the detection of favourable effects even in the absence of prolonged mesenchymal stromal cell engraftment at sites of injury 12, 74, 75 . These findings have prompted clinical studies on the therapeutic potential of mesenchymal stromal cells. For instance, the osteogenic properties of mesenchymal stromal cells have been used to treat children with osteogenesis imperfecta and have shown promising outcomes 79, 80 . On the basis of their immunoregulatory and tissue-protective properties, mesenchymal stromal cells are also being tested for the treatment and prevention of graft-versus-host disease, Crohn's disease and certain haematological malignancies 78, 81, 82 . Nevertheless, in most cases these studies are preliminary, and treatment efficacy has not been conclusively established. Some of the major problems that still need to be resolved concern the standardization of protocols for the isolation of mesenchymal stem cells and their expansion into mesenchymal stromal cells in vitro, the safety of such cell-based therapies and the homing and engraftment of mesenchymal stromal cells to their target tissues.
Dendritic cell
Collectively, these results strongly suggest that the precursors of cultured mesenchyma l stromal cells preferentially reside close to blood vessels in vivo, a trait that is not unique to MSCs but that is pertinent to other multipotent stem or progenitor cells present in adult tissues. In this respect, HSCs (dis cussed below), as well as white fat progenitor cells and skeletal muscle stem cells (other illdefined tissue progenitors), have been reported to reside in perivascular spaces of bone marrow, adipose tissue and skeleta l muscle microvessels, respectively [56] [57] [58] [59] . Nevertheless, it is important to note that the terms pericyte and MSC are not equivalent or interchangeable. Although widely used to refer to cells surrounding blood vessels, the word pericyte strictly refers to cells adjacent to capillaries and postcapillary venules 49 ; however, multipotent MSClike precursors have been isolated from the walls of other vascular types, including arteries and veins 60, 61 . Furthermore, because peri cytes show an extensive tissue distribution along diverse microvascular beds and have many proposed functions (including vessel stabil ization, phagocytosis and regulation of vascular integrity and tone 49 ), it is likely that functionally heterogeneous, nonequivalent cell subsets are included under the vague term pericyte. Thus, despite being peri vascular, not all MSCs can be referred to as pericytes, and not all pericytes exhibit MSCspecific properties.
MSCs and haematopoiesis
The stromal compartment of the BM was the first biological material from which MSCs were isolated. Since then, BMderived MSCs have been the most widely studied and are the best character ized, and they are now thought to be key regulators of BM physiology (FIG. 2) .
Precursors of the haematopoietic microenvironment. During adulthood, the sustained production of blood cells occurs primarily in the BM. MSCs have long been proposed to be the in vivo precursors of some of the non haematopoietic components of the BM that regulate haematopoiesis, such as osteoblasts, adipocytes and fibroblastic reticular cells 2 . Consequently, MSCs are likely to contribute to the homeostasis of the haematopoietic compartment in vivo through the regulatory properties of their mature progeny (FIG. 2) .
Inside the BM microenvironment, HSCs are thought to reside in confined niches, which are created by surrounding cells, solu ble factors and extracellular matrix proteins that ultimately promote HSC maintenance.
Osteoblasts have been postulated to crucially contribute to HSC niches and to regulate HSC homeostasis through direct celltocell interactions 62, 63 . Although the existence of an osteoblastic HSC niche is controversial 64 , it seems clear that, either directly or through the secretion of soluble factors, osteoblasts are essential constituents of the BM micro environment and have regulatory roles at many stages of haematopoietic development (reviewed in ReF. 65) . The BM stroma is also composed of MSCderived adipocytes, which function as negative regulators of early haematopoietic progenitors through unknown molecular mechanisms 66 . Hence, MSCs are the source of two coexisting mature cell types with apparently antagonistic properties on HSCs. Many open questions remain concerning the precise developmental stages that MSCs undergo during differentiation in situ, the pathways governing lineage commitment decisions in vivo and the global impact of the balance of osteoblast and adipocyte production in haematopoietic environments (FIG. 2) .
HSC niche components. Multipotent, im mature BMresident MSCs have long been proposed to provide modulatory sig nals to haematopoietic progenitors, based on the fact that mixed cultures derived from the adherent fraction of BM stroma promote survival and proliferation of HSCs ex vivo 67 . In addition, MSCs are isolated from all fetal haematopoietic sites even before the HSC colonization of those tissues 10, 68 . It is there fore thought that MSCs have a key role in the organization of HSC niches, either through direct interaction or, as proposed in ReF. 13 , through their reported ability to organize vascular networks, which are key structural and functional components of haemato poietic sites 45, 69 . Indeed, the existence of a 'dual stem cell niche' , in which MSCs and HSCs directly interact in perivascular spaces of the BM, is conceptually attractive and has been proposed in two recent publications. HSCs have been shown to colocalize with a subset of poorly characterized fibroblastic reticular cells that are defined by high expres sion of CXC chemokine ligand 12 (CXCl12; also known as SDF1) and are known as CXCl12abundant reticular cells (CARCs) 70 . These cells have osteogenic and adipogenic potential and might therefore correspond to, or immediately derive from, MSCs 71 . Moreover, an association between HSCs and BMresident MSCs has been visualized using mice expressing nestin tagged with green fluorescent protein (nestin-GFP) 47 . Selective depletion of CARCs or nestin-GFP + MSCs, both of which express high levels of HSCregulatory factors, had a direct impact on HSC numbers and homeostasis, further indicating a role for BMresident MSCs in HSC biology 47, 71 . Notably, nestin-GFP + BMresident MSCs are directly innervated and respond to signals from the sympathetic nervous system (SNS) 47 , thus providing a link by which HSC homeostasis is regulated by the SNS, as had been pre viously demonstrated 72, 73 . Further studies are needed to fully understand where and how HSCs, MSCs and the SNS interact.
Immunomodulatory agents. One of the most remarkable and unforeseen aspects of mesenchymal stromal cells pertains to their immunomodulatory activity (reviewed in ReFs 74, 75) . In vitro, mesenchymal stromal cells inhibit T cell activation, dendritic cell differentiation and B cell proliferation, and impair the cytolytic potential of natural killer cells. Immunosuppression after MSC infu sion in vivo has also been documented in diverse animal models of disease 12, 74 . These effects are partially explained by the ability of mesenchymal stromal cells to secrete a vast array of soluble mediators, some of which have immunomodulatory properties: for example, interleukin10 (Il10), prosta glandin e2, nitric oxide and transforming growth factorβ (TGFβ) 12 . Nevertheless, these immunomodulatory effects require, at least in part, direct cellto cell contact. Notably, immunomodulation in vitro and in vivo has been reported exclusi vely for mesenchymal stromal cells, and no evidence exists to date to suggest that such regulatory properties can be ascribed to MSCs in vivo. However, given that the BM is one of the sites where adap tive immune responses are generated, and that BMresident MSCs share perisinu soidal locations with dendritic cells and circulating B cells 76, 77 , it seems plausible that MSC-immune cell interactions may be of physiological relevance, a possibility that merits further investigation (FIG. 2) .
Concluding remarks
The discovery of a subset of adult multi potent cells that could be readily purified by adherence from multiple tissues and rapidly expanded ex vivo was enthusiasti cally received, in the hope that these would become an alternative to embryonic stem cells and be free of the ethical implica tions associated with the therapeutic application of these embryonic cells in humans. As a consequence, investigations oriented towards characterizing mesen chymal stromal cells and harnessing their therapeutic potential (BOX 2) rapidly pro liferated, whereas fundamental biological questions regarding their in vivo counterpart populations remained largely unanswered. In our view, the term MSC is misleading, in that it has been widely used to refer to a heterogeneous pool of tissuespecific multipotent perivascular progenitors, which are likely to possess diverse in vivo functions and differentiation potential but have similar features after in vitro culture. Among these progenitors, the only wellcharacterized cells, in terms of biological properties and in vivo stem cell features, are BMresident MSCs, which sustain the homeostatic turnover of skeletal cell types in the BM in vivo.
Major challenges at hand are to define the biological equivalence and hierarchical relationships between progenitors in diverse anatomical locations, understand their developmental origin, characterize their multipotential capabilities and elucidate their in vivo roles during homeostasis and tissue repair. Resolving these problems will require comprehensive experimental approaches, including the use of stringent in vivo assays to define the multipotency of MSC populations, advanced in vivo micro scopy techniques to track their distribution and dynamics in diverse tissues and induc ible genetic MSCspecific animal models. Ultimately, a more refined insight into the biological attributes of MSCs is expected to result in a more rational exploitation of their therapeutic use.
